Minerva Neurosciences Inc (NERV)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.43-5.54%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NERV
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Execute the global confirmatory Phase 3 clinical trial (C19 Study) for roluperidone targeting negative symptoms of schizophrenia with topline data expected 2H 2027.
Stated as a priority in 2 of last 2 quarters. R&D expenses increased from $5.3 million in 2026-Q1 to $7.2 million in 2026-Q2, reflecting investment in the C19 Phase 3 trial. Management remains focused on execution with topline efficacy data expected in 2H 2027, indicating delivery aligned with stated plans.
“Confirmatory Phase 3 trial of roluperidone ongoing with topline efficacy data expected 2H 2027.”
“Minerva initiated its global confirmatory Phase 3 clinical trial of roluperidone with efficacy topline data expected 2H 2027.”
Maintain financial resources through equity issuance and manage liabilities to support ongoing operations and clinical development.
Stated as a priority in 2 of last 2 quarters. The company secured a securities purchase agreement for up to $200 million and established an 'at-the-market' equity offering program. Cash and equivalents decreased modestly from $82.4 million at 2025-FY to $75.4 million at 2026-Q2, while total liabilities increased from $233.8 million to $296.6 million, reflecting ongoing capital management consistent with stated priorities.
“Entered into Sales Agreement for 'at-the-market' offering program to issue and sell common stock.”
“Entered into securities purchase agreement with institutional investors for up to $200 million in gross proceeds.”
Manage executive leadership changes including appointment of new Chief Business Officer and transition of President role.
Stated as a priority in 2 of last 2 quarters. Management announced the resignation of President Geoff Race and appointment of Jim O'Connor as Chief Business Officer and General Counsel. The transition is ongoing with the former President acting as consultant, indicating active management of leadership changes consistent with stated priorities.
“Leadership transition ongoing with new Chief Business Officer appointed and former President serving as consultant.”
“Announced leadership transition with Jim O'Connor joining as Chief Business Officer and General Counsel; President resigned.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Over the trailing year it converted 0.15x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
11 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.